CRNX

Crinetics Pharmaceuticals Inc

Feb 03 • 04:00PM ET

49.96

+0.61 1.24 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX LLY PFE NVS BMRN VRTX REGN SNY MRK BMY

| Held by: VTI IWM VB VBK VXF IWO IBB SCHA VTWO IHE

Index	RUT	P/E	-	EPS (ttm)	-4.53	Insider Own	7.14%	Shs Outstand	102.51M	Perf Week	-5.67%
Market Cap	5.12B	Forward P/E	-	EPS next Y	-4.97	Insider Trans	-1.07%	Shs Float	95.19M	Perf Month	6.91%
Enterprise Value	4.08B	PEG	-	EPS next Q	-1.35	Inst Own	102.28%	Short Float	15.79%	Perf Quarter	14.85%
Income	-423.10M	P/S	3347.38	EPS this Y	-36.38%	Inst Trans	2.58%	Short Ratio	11.10	Perf Half Y	77.04%
Sales	1.53M	P/B	4.41	EPS next Y	1.22%	ROA	-39.66%	Short Interest	15.03M	Perf YTD	7.33%
Book/sh	11.34	P/C	4.69	EPS next 5Y	-0.76%	ROE	-44.42%	52W High	57.99 -13.85%	Perf Year	23.97%
Cash/sh	10.66	P/FCF	-	EPS past 3/5Y	-9.67% -12.11%	ROIC	-37.95%	52W Low	24.10 107.30%	Perf 3Y	144.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.22% -	Gross Margin	-140.00%	Volatility	4.76% 5.94%	Perf 5Y	245.27%
Dividend TTM	-	EV/Sales	2665.26	EPS Y/Y TTM	-21.96%	Oper. Margin	-31130.16%	ATR (14)	2.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.12	Sales Y/Y TTM	-	Profit Margin	-27563.32%	RSI (14)	44.92	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	15.12	EPS Q/Q	-43.94%	SMA20	-5.78%	Beta	0.19	Target Price	85.14
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	1.14%	Rel Volume	0.61	Prev Close	49.35
Employees	437	LT Debt/Eq	0.04	Earnings	Feb 26 AMC	SMA200	31.07%	Avg Volume	1.35M	Price	49.96
IPO	Jul 18, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.90% -66.73%	Trades		Volume	828,304	Change	1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-26	Upgrade	Goldman	Neutral → Buy	$67
Jul-10-25	Initiated	Goldman	Neutral	$36
Mar-25-25	Initiated	Stifel	Buy	$60
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy	$55
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40

Show Previous Ratings

Jan-26-26 05:00PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-22-26 04:05PM	Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
03:09AM	Jim Cramer on Crinetics: "That's a Better Spec Than Aquestive" (Insider Monkey)
Jan-17-26 06:03AM	Markets Climb Wall-of-Worry: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy (TipRanks)
Jan-15-26 11:35AM	Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral (Insider Monkey)
04:05PM	Loading…
Jan-12-26 04:05PM	Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-26 09:22PM	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +16.08%
Jan-05-26 04:02PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia (GlobeNewswire)
Jan-04-26 04:00PM	Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (GlobeNewswire)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire) +6.36%
Dec-18-25 04:05PM	Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.35%
Dec-11-25 04:05PM	Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
07:44AM	Crinetics Pharmaceuticals, Inc. (CRNX) Poised for Transformational Growth in 2026: Piper Sandler (Insider Monkey)
Dec-10-25 04:34PM	Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Dec-03-25 08:00AM	Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors (GlobeNewswire)
Nov-20-25 04:05PM	Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome (GlobeNewswire)
Nov-10-25 04:28PM	Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-25 04:16PM	Why Crinetics Pharmaceuticals Stock Was Sliding on Friday (Motley Fool) -8.02%
Nov-06-25 05:20PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-23-25 08:00AM	Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting (GlobeNewswire)
Oct-10-25 04:41PM	Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-25 01:04PM	Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) (Insider Monkey)
Oct-06-25 04:05PM	Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Sep-30-25 11:49AM	JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval (Insider Monkey)
04:01AM	JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating (Insider Monkey)
Sep-29-25 06:54PM	Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug (Insider Monkey) -5.23%
Sep-28-25 08:30AM	Is Crinetics Pharmaceuticals Stock a Buy? (Motley Fool)
Sep-26-25 04:22PM	Crinetics Pharma Surges After FDA OKs Its Treatment For Growth Disorder (Investor's Business Daily) +27.92% -5.23%
01:07PM	Loading…
01:07PM	FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder (Benzinga)
09:14AM	Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism (Investor's Business Daily)
Sep-25-25 05:30PM	Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Adults with Acromegaly (GlobeNewswire)
Sep-10-25 04:30PM	Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:21PM	CTSWC25: The future of clinical trial supply hinges on risk management (Clinical Trials Arena)
Aug-21-25 08:45AM	Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Aug-11-25 04:05PM	Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-25 05:55PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:56AM	Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data (Insider Monkey)
10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline (Zacks)
Jul-16-25 09:38AM	Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs (Insider Monkey)
Jul-14-25 05:53AM	Crinetics reveals new data from acromegaly therapy programme (Clinical Trials Arena)
Jul-13-25 05:45PM	Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025 (GlobeNewswire)
Jul-11-25 08:00AM	Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:28PM	Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-25 08:21AM	Should You Hold Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jul-03-25 08:17AM	Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? (Zacks)
Jun-30-25 04:05PM	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline (GlobeNewswire)
Jun-16-25 08:00AM	Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 (GlobeNewswire)
Jun-10-25 04:29PM	Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-23-25 08:00AM	Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-15-25 04:05PM	Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 (GlobeNewswire)
May-12-25 04:05PM	Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.60% -7.11%
May-09-25 01:01PM	Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com) -6.18%
08:48AM	Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-08-25 05:40PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 09:57AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings (GuruFocus.com)
Apr-11-25 08:00AM	Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire) +8.42%
Apr-10-25 05:04PM	Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-25 02:15PM	Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA (Seeking Alpha)
Mar-27-25 04:05PM	Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly (GlobeNewswire)
Mar-10-25 04:36PM	Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.74%
03:24PM	Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-26-25 07:26AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 08:30AM	Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer (GlobeNewswire) -7.58%
Feb-20-25 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences (GlobeNewswire)
Feb-10-25 04:44PM	Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:35PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-05-25 04:57PM	Crinetics Pharmaceuticals, Inc. (CRNX): One of Januarys Biggest Losers (Insider Monkey)
Jan-29-25 05:37PM	What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jan-21-25 04:10PM	Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-17-25 11:12AM	Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-10-25 05:15PM	Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -16.31%
07:00AM	Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Jan-06-25 08:00AM	Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.00%
Dec-16-24 08:00AM	Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer (GlobeNewswire)
Dec-10-24 08:44PM	Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.21%
06:22AM	FDA accepts Crinetics Pharmaceuticals' NDA for acromegaly treatment therapy (Pharmaceutical Business Review)
Dec-09-24 08:00AM	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly (GlobeNewswire)
Nov-15-24 09:00AM	Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences (GlobeNewswire) -8.28%
Nov-14-24 04:05PM	UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
Nov-13-24 02:18AM	Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 04:07PM	Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 04:05PM	Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-17-24 03:09PM	State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals (GuruFocus.com)
Oct-16-24 08:00AM	Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-10-24 04:40PM	Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 05:56PM	Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 11:55PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-26-24 04:05PM	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly (GlobeNewswire)
Sep-12-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) +5.02%
Sep-10-24 04:40PM	Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DANA PIZZUTI	Officer	Feb 02 '26	Proposed Sale	49.94	10,000	499,400		Feb 02 04:32 PM
Kalofonos Isabel	Chief Commercial Officer	Jan 05 '26	Option Exercise	40.59	2,500	101,475	3,334	Jan 07 05:11 PM
Kalofonos Isabel	Chief Commercial Officer	Jan 05 '26	Sale	55.00	2,500	137,500	834	Jan 07 05:11 PM
ISABEL KALOFONOS	Officer	Jan 05 '26	Proposed Sale	46.73	2,500	116,825		Jan 05 04:43 PM
DANA PIZZUTI	Officer	Jan 02 '26	Proposed Sale	46.55	5,000	232,750		Jan 02 04:31 PM
Betz Stephen F.	Chief Scientific Officer	Dec 26 '25	Option Exercise	1.91	18,000	34,380	117,713	Dec 29 04:36 PM
Struthers Richard Scott	President & CEO	Dec 18 '25	Option Exercise	13.09	44,742	585,890	364,759	Dec 18 06:54 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 01 '25	Option Exercise	16.89	5,000	84,450	71,837	Dec 03 04:28 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 01 '25	Sale	45.02	5,000	225,100	66,837	Dec 03 04:28 PM
DANA PIZZUTI	Officer	Dec 01 '25	Proposed Sale	45.56	5,000	227,800		Dec 01 04:37 PM
Pizzuti Dana	Chief Med and Dev Officer	Nov 03 '25	Option Exercise	16.89	5,000	84,450	71,270	Nov 05 05:00 PM
Pizzuti Dana	Chief Med and Dev Officer	Nov 03 '25	Sale	42.66	5,000	213,312	66,270	Nov 05 05:00 PM
DANA PIZZUTI	Officer	Nov 03 '25	Proposed Sale	43.50	5,000	217,500		Nov 03 04:26 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 01 '25	Option Exercise	16.89	5,000	84,450	71,270	Oct 03 04:41 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 01 '25	Sale	41.81	5,000	209,050	66,270	Oct 03 04:41 PM
DANA PIZZUTI	Officer	Oct 01 '25	Proposed Sale	41.65	5,000	208,250		Oct 01 04:30 PM
Struthers Richard Scott	President & CEO	Sep 26 '25	Sale	45.00	4,000	180,000	106,000	Sep 30 04:42 PM
Fust Matthew K	Director	Sep 26 '25	Option Exercise	1.91	10,000	19,100	38,836	Sep 30 04:41 PM
Fust Matthew K	Director	Sep 26 '25	Sale	44.75	16,000	716,000	22,836	Sep 30 04:41 PM
MATTHEW K FUST	Director	Sep 26 '25	Proposed Sale	35.89	16,000	574,240		Sep 26 04:27 PM
Struthers Richard Scott	Officer	Sep 26 '25	Proposed Sale	45.00	4,000	180,000		Sep 26 04:09 PM
Pizzuti Dana	Chief Med and Dev Officer	Sep 02 '25	Option Exercise	16.89	5,000	84,450	101,270	Sep 04 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Sep 02 '25	Sale	32.10	5,000	160,500	96,270	Sep 04 04:30 PM
DANA PIZZUTI	Officer	Sep 02 '25	Proposed Sale	30.99	5,000	154,950		Sep 02 04:41 PM
Pizzuti Dana	Chief Med and Dev Officer	Aug 22 '25	Option Exercise	16.89	30,000	506,700	96,270	Aug 26 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Aug 22 '25	Sale	30.43	30,000	912,900	66,270	Aug 26 04:30 PM
DANA PIZZUTI	Officer	Aug 22 '25	Proposed Sale	29.40	30,000	882,000		Aug 22 04:44 PM
Pizzuti Dana	Chief Med and Dev Officer	Aug 20 '25	Sale	29.18	6,492	189,437	66,270	Aug 21 04:30 PM
DANA PIZZUTI	Officer	Aug 20 '25	Proposed Sale	29.43	6,492	191,060		Aug 20 04:24 PM
Betz Stephen F.	Chief Scientific Officer	Jun 12 '25	Option Exercise	3.30	88,170	291,078	197,196	Jun 16 04:48 PM
Betz Stephen F.	Chief Scientific Officer	Jun 12 '25	Sale	32.23	97,483	3,141,877	99,713	Jun 16 04:48 PM
STEPHEN BETZ	Officer	Jun 12 '25	Proposed Sale	32.33	97,483	3,151,625		Jun 12 04:19 PM
Struthers Richard Scott	President & CEO	Apr 02 '25	Option Exercise	1.91	81,270	155,226	410,417	Apr 04 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 19 '25	Sale	34.20	2,515	86,021	72,233	Mar 21 06:34 PM
Knight Jeff E.	Chief Operating Officer	Mar 19 '25	Sale	34.20	7,162	244,964	87,491	Mar 21 06:33 PM
Betz Stephen F.	Chief Scientific Officer	Mar 19 '25	Sale	34.20	5,770	197,353	108,588	Mar 21 06:32 PM
Struthers Richard Scott	President & CEO	Mar 19 '25	Sale	34.20	17,338	593,017	329,147	Mar 21 06:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRNX

Crinetics Pharmaceuticals Inc

Upgrade your FINVIZ experience